Bone Biologics CEO updates on NB1 trial enrollment, shelf life extension, and $5M offering

Bone Biologics Corp

Clinical trial enrollment slower than anticipated; expects to complete enrollment by year-end 2025.
Achieved 18-month shelf life for NB1 protein, up from 12 months; plan to extend to 24 months.
Filed U.S. patent application in June 2025 for proprietary rhNELL-1 compositions for bone conditions.
Raised $5M gross in June public offering; expects cash to fund operations into Q2 2026.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.